Challenges and opportunities in delivering oral peptides and proteins
H Peng, J Wang, J Chen, Y Peng, X Wang… - Expert opinion on …, 2023 - Taylor & Francis
Introduction Rapid advances in bioengineering enable the use of complex proteins as
therapeutic agents to treat diseases. Compared with conventional small molecule drugs …
therapeutic agents to treat diseases. Compared with conventional small molecule drugs …
Recent advances in drug discovery for triple-negative breast cancer treatment
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …
Design, synthesis and biological evaluation of N-benzylaryl cinnamide derivatives as tubulin polymerization inhibitors capable of promoting YAP degradation with …
XJ Fu, J Huang, N Li, YH Liu, QG Liu, S Yuan… - European Journal of …, 2023 - Elsevier
In this work, we utilized the N-benzylaryl derivative 9 as a lead compound and employed the
molecular hybridization strategy by introducing cinnamoyl fragments to successfully design …
molecular hybridization strategy by introducing cinnamoyl fragments to successfully design …
SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis
S Deng, S Banerjee, H Chen, S Pochampally, Y Wang… - Cancer letters, 2023 - Elsevier
Extensive preclinical studies have shown that colchicine-binding site inhibitors (CBSIs) are
promising drug candidates for cancer therapy. Although numerous CBSIs were generated …
promising drug candidates for cancer therapy. Although numerous CBSIs were generated …
Design, synthesis, and biological evaluation of pyrimidine dihydroquinoxalinone derivatives as tubulin colchicine site-binding agents that displayed potent anticancer …
S Pochampally, KL Hartman, R Wang… - ACS Pharmacology & …, 2023 - ACS Publications
Polymerization of tubulin dimers to form microtubules is one of the key events in cell
proliferation. The inhibition of this event has long been recognized as a potential treatment …
proliferation. The inhibition of this event has long been recognized as a potential treatment …
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel …
J Yang, D Song, B Li, X Gao, Y Wang, X Li, C Bao… - Drug Resistance …, 2023 - Elsevier
Aims Microtubule inhibitors are widely used in first line cancer therapy, though drug
resistance often develops and causes treatment failure. Colchicine binds to tubulins and …
resistance often develops and causes treatment failure. Colchicine binds to tubulins and …
Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl) azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells
S Wang, AM Malebari, TF Greene, S Kandwal… - Pharmaceuticals, 2023 - mdpi.com
A series of novel 3-(prop-1-en-2-yl) azetidin-2-one, 3-allylazetidin-2-one and 3-(buta-1, 3-
dien-1-yl) azetidin-2-one analogues of combretastatin A-4 (CA-4) were designed and …
dien-1-yl) azetidin-2-one analogues of combretastatin A-4 (CA-4) were designed and …
[HTML][HTML] PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
Background: Poly (ADP-ribose) polymerases 1 and 2 (PARP1, 2), and 3 mediate protein
modifications that facilitate the recruitment of DNA repair factors to single and double strand …
modifications that facilitate the recruitment of DNA repair factors to single and double strand …